Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Average PT from Analysts
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) have earned a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month […]
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) have earned a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month […]
